The world's largest randomized trial of COVID-19 treatments found conclusive evidence that remdesivir, a drug used, has little or no effect on severe cases, AP cited the U.N. health agency as saying Friday. The World Health Organization announced the long-awaited results of a six-month trial that endeavored to see if existing drugs might have an effect on the coronavirus. The study, which was not peer-reviewed, found that four treatments tested remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon had little or no effect" on whether or not patients died within about a month or whether hospitalized patients recovered. Most of those had already been ruled out. But remdesivir, an antiviral, has been classified as standard-of-care in the United States, and it has been approved for use against COVID-19 in the UK and EU. Supplies of the drug have been limited, and the European Medicines Agency is now reviewing whether remdesivir is causing kidney problems as reported by some patients. The results of the global trial are in sharp contrast to a large study in the United States, which found remdesivir shortened the time to recovery by about five days on average. Martin Landray, a professor of medicine and epidemiology at Oxford University, said the WHO trial results for hydroxychloroquine and lopinavir were in line with a previous British study he co-led. The big story is the finding that remdesivir produces no meaningful impact on survival, he said in a statement, adding that the drug is now recommended in some countries, but there have been significant concerns about supply, cost and access.
